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Worldwide, non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality and, until screening detects early
disease, treatment for the majority of patients will consist of radiation therapy, chemotherapy or combinations thereof. Modern
mono and doublet chemotherapy regimens have translated into modest increases in life expectancy and improved quality of life, but
at the expense of systemic and pulmonary adverse events (AEs). There is a great unmet need to provide effective therapy for
advanced NSCLC that does not have the toxicity burden of conventional chemotherapy and radiotherapy. Novel drugs that inhibit a
range of growth factor receptors, such as the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib (‘Iressa’) and
erlotinib (‘Tarceva’) or the monoclonal antibody cetuximab (‘Erbitux’), have recently been evaluated. Having demonstrated
antitumour activity and rapid symptom improvement in pretreated patients with advanced NSCLC, gefitinib was approved in the
USA, Japan and other countries. Gefitinib is well tolerated with a low incidence of grade 3/4 AEs. Interstitial lung disease has been
reported in a small number of patients receiving gefitinib, although this may be attributed to other treatments and conditions.
Nevertheless, although the use of novel treatments requires vigilance for unexpected AEs such as pulmonary toxicity, in this area of
high unmet clinical need, the benefits outweigh the risks in patients for whom no other proven effective treatment exists.
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NON-SMALL-CELL LUNG CANCER (NSCLC)
Lung cancer is one of the most common malignancies in developed
countries and accounts for millions of deaths worldwide. In 2000,
the annual incidence of NSCLC, which comprises 80% of all lung
cancer cases, was 991089 and the worldwide mortality was 882495
(Ferlay et al, 2001).
At diagnosis, patients with NSCLC can be divided into three
groups, reflecting disease extent and treatment approach. The first
group, patients with stage I and II disease, has the best prognosis
and surgery is the treatment of choice; however, patients with
inoperable disease might be considered for radiation therapy with
curative intent. Careful preoperative assessment of the patient’s
overall pulmonary reserve is essential in considering surgery. The
second group of patients (stage III) includes those with locally or
regionally advanced NSCLC. These patients are often treated with
combined modality treatment, that is, various combinations of
chemotherapy, radiation therapy and surgery. Patients in the final
group (stage IV) have advanced disease with distant metastases
and can be treated with radiation therapy and/or chemotherapy.
Unfortunately, the prognosis of patients with advanced NSCLC
remains poor. Systemic chemotherapy prolongs survival compared
with best supportive care alone, as demonstrated in patients
treated with platinum-based regimens (Non-small Cell Lung
Cancer Collaborative Group, 1995). However, chemotherapeutic
regimens are associated with systemic (Table 1) (Schiller et al,
2002) and pulmonary adverse events (AEs). Furthermore, debil-
itating pulmonary and general symptoms are of central concern to
patients with advanced NSCLC and lead to severe reductions in
quality of life (QoL). The quest is for more effective therapeutic
strategies for NSCLC that carry fewer AEs and that balance the
clinical benefit gained, including symptom relief, against those
AEs.
ADVANCES IN THE CHEMOTHERAPY OF NSCLC
The new chemotherapy regimens
Over the past decade, older chemotherapy regimens have been
replaced by a number of new chemotherapy agents for the
treatment of NSCLC, including the taxanes (paclitaxel and
docetaxel), gemcitabine and vinorelbine. Vinorelbine in combina-
tion with cisplatin was the first novel combination regimen to
produce a statistically significant survival advantage over a
standard regimen (vindesine plus cisplatin) (Le Chevalier et al,
1994). Subsequently, in a randomised phase III trial, the Southwest
Oncology Group confirmed the efficacy of vinorelbine plus
cisplatin for patients with metastatic NSCLC (Wozniak et al,
1998). Several studies have been performed to compare recent
doublet regimens.
A randomised phase III trial compared paclitaxel plus
carboplatin with vinorelbine plus cisplatin in patients with *Correspondence: Dr A Onn; E-mail: amironn@mdanderson.org
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was observed between the two treatment arms, with objective
response rates of 25 and 28%, median survival times of 8 months
in both arms and 1-year survival rates of 38 and 36%, respectively.
Less toxicity was observed with the paclitaxel plus carboplatin
regimen.
The Eastern Cooperative Oncology Group (ECOG) reported
results from a randomised trial in patients with advanced
NSCLC that compared the efficacy of a reference regimen of
cisplatin and paclitaxel with three experimental regimens:
cisplatin and gemcitabine, cisplatin and docetaxel, and carbo-
platin and paclitaxel (Schiller et al, 2002). The response rate and
survival did not differ significantly between patients assigned
to receive cisplatin and paclitaxel and those assigned to receive
any of the three experimental regimens (Figure 1) (Schiller et al,
2002). However, there was a suggestion that time to progression
was more favourable with the gemcitabine combination. Treat-
ment with cisplatin and gemcitabine was more likely to cause
grade 3, 4 or 5 renal toxicity, while the combination of carboplatin
and paclitaxel was considered, comparatively, to be the most
tolerable.
Results from a randomised phase III trial of docetaxel plus
platinum regimens vs vinorelbine plus cisplatin for first-line
therapy of advanced NSCLC were recently reported (Fossella et al,
2003). A more favourable overall response and survival rate was
observed in patients treated with a docetaxel regimen than the
vinorelbine combination: overall response rates were 31.6 and
24.5% for patients treated with docetaxel and vinorelbine,
respectively (P¼0.029); median survival was 11.3 months and
10.1 months, respectively. Compared with vinorelbine plus
cisplatin, the docetaxel regimen was better tolerated and
consistently improved QoL.
Three-drug combinations might also be an option for treatment
of NSCLC. However, at least two randomised trials found no
benefit for chemotherapy triplets over doublets (Pirker, 2002) and,
as toxicity is likely to be high, there is no justification for
increasing the number of chemotherapy drugs in a treatment
regimen beyond two unless the benefit:risk ratio has been
demonstrated to be favourable.
Cisplatin or carboplatin regimens?
A number of first-line chemotherapy options are advocated in
treatment guidelines and/or by various clinical investigators for
the treatment of patients with advanced NSCLC. Platinum-based
chemotherapy has clearly demonstrated efficacy in patients with
advanced NSCLC and there is increasing interest in the use of
nonplatinum chemotherapy regimens. Regimens such as cisplatin
or carboplatin combined with paclitaxel, vinorelbine, gemcitabine,
docetaxel or irinotecan are among the platinum-based combina-
tions currently used in clinical practice. The particular combina-
tions employed may vary between institutions and geographical
regions and, although a number of studies have compared
cisplatin- with carboplatin-based regimens, no definitive evidence
suggests either agent to be better. An early ECOG study compared
three cisplatin-based regimens with single-agent carboplatin, and
the results demonstrated that carboplatin-treated patients had
better overall survival and less toxicity than cisplatin-based
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Figure 1 Survival of patients with stage IV NSCLC receiving four
different platinum-based combination chemotherapy regimens (Schiller
et al, 2002). Reprinted with permission from: Schiller et al (2002).
Copyright r 2002 Massachusetts Medical Society. All rights reserved.
Table 1 Common AEs associated with cancer therapy (Schiller et al, 2002)
Treatment Drug dose and regimen Highest grade (all AEs, %) Most common grade 3/4 AEs
Cisplatin and paclitaxel Paclitaxel 135mgm
 2 over 24-h period Grade 3 (19) Absolute neutrophil count
n¼300 on day 1; Grade 4 (68) Nausea
Cisplatin 75mgm
 2 on day 2; Grade 5 (5) Vomiting
Repeat cycle every 21 days Febrile neutropenia
Cisplatin and gemcitabine Gemcitabine 1000mgm
 2 on days 1, 8, Grade 3 (21) Absolute neutrophil count
n¼293 15; Grade 4 (68) Platelet count
Cisplatin 100mgm
 2 on day 1; Grade 5 (4) Nausea
Repeat cycle every 28 days Vomiting
Cisplatin and docetaxel Docetaxel 75mgm
 2 on day 1; Grade 3 (23) Absolute neutrophil count
n¼287 Cisplatin 75mgm
 2 on day 1; Grade 4 (61) Nausea
Repeat cycle every 21 days Grade 5 (6) Vomiting
Weakness
Carboplatin and paclitaxel Paclitaxel 225mgm
 2 over 3-h period Grade 3 (28) Absolute neutrophil count
n¼293 on day 1; Grade 4 (53) Weakness
Carboplatin, AUC 6.0mgml
 1min
 1 on Grade 5 (4) Platelet count
day 1; Anaemia
Repeat cycle every 21 days
AE¼adverse events. Adapted with permission from Schiller et al (2002). Copyright r 2002 Massachusetts Medical Society. All rights reserved.
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study that compared cisplatin and carboplatin in combination with
vindesine and mitomycin C indicated a survival advantage for the
carboplatin regimen (Jelic et al, 2001). In contrast, a paclitaxel/
cisplatin regimen was better than a carboplatin regimen (Rosell
et al, 2002) and no significant differences in survival were apparent
in a further trial comparing cisplatin and etoposide with
carboplatin and etoposide by the European Organisation for
Research and Treatment of Cancer (Klastersky et al, 1990).
Chemotherapy in the elderly and poor performance status
(PS) patients
Approximately one-third of all patients with NSCLC are 470 years
of age and, although these patients are likely to have an increased
risk of comorbid conditions and impaired organ function, most
studies have suggested that age alone should not be a factor in the
decision to treat patients with chemotherapy. A retrospective study
of patients treated for advanced NSCLC found no major
differences between patients older or younger than 65 years of
age (Giovanazzi-Bannon et al, 1994), and an analysis of age as a
risk factor in chemotherapy trials found that the response, toxicity
and survival rates of elderly patients were similar to those of
younger patients (Langer et al, 2002).
Two important phase III randomised studies of chemotherapy
in the elderly have been reported (Fossella et al, 2000; Gridelli,
2001). The Elderly Lung Cancer Vinorelbine Italian Study group
performed a multicentre, randomised trial of single-agent vinor-
elbine as a first-line agent in elderly patients with advanced
NSCLC. Results demonstrated that the addition of vinorelbine to
best supportive care significantly prolonged survival in this group
of patients (Gridelli, 2001). The median survival for best
supportive care plus vinorelbine was 28 weeks compared with
21 weeks for best supportive care alone. This benefit was achieved
at the cost of some drug-related toxicity, reflected in lower scores
on QoL subscales that were directly related to drug toxicity
(e.g. nausea and constipation). However, patients who received
vinorelbine scored better than control patients on overall health
status and QoL, and suffered less from the lung cancer symptoms
of dyspnoea, cough and haemoptysis.
More recently, the Multicentre Italian Lung cancer in the Elderly
Study randomised elderly patients with advanced NSCLC to
vinorelbine, gemcitabine or vinorelbine plus gemcitabine (Gridelli
et al, 2003). Results demonstrated that the combination of
gemcitabine plus vinorelbine in this patient population does not
improve survival or QoL compared with single-agent chemother-
apy with vinorelbine or gemcitabine. The combination treatment
was more toxic than the agents administered alone.
Overall, the studies in elderly patients with NSCLC demonstrate
that chemotherapy regimens can lead to an improvement in
survival with a better QoL. However, careful attention should be
paid to the toxicity of treatment regimens and the coexisting
comorbidities in this patient population.
For PS 2 patients, the benefit of chemotherapy remains to be
conclusively demonstrated. A survival advantage in this group of
patients was demonstrated for carboplatin and paclitaxel com-
pared with single-agent paclitaxel in a phase III randomised trial
(Lilenbaum et al, 2002). The median survival was 4.7 months for
the combination of paclitaxel and carboplatin and 2.4 months for
paclitaxel alone. At 1 year, survival rates were 18% for the
combination compared with 10% for paclitaxel alone. The outcome
of patients with PS 2 was also reported in an ECOG study that
compared paclitaxel and cisplatin with three newer chemotherapy
doublets in the treatment of patients with advanced NSCLC
(Sweeney et al, 2001). In this study, patients with PS 2 experienced
a large number of AEs and overall poor survival. The overall
median survival of all 68 patients who enrolled was 4.1 months.
A comparison with patients with a PS of 0–1 suggests
that the shorter survival in patients with a PS of 2 was related to
tumour progression rather than treatment. Alternative strategies
specifically tailored for this group of patients need to be further
explored.
Advances in second-line chemotherapy
With increased use of chemotherapy, the number of patients
seeking second-line therapy after relapse following first-line
treatment has increased. Available treatments for second-line
therapy are limited and patients with tumour progression at this
stage generally have very poor prognoses.
The TAX 320 NSCLC Study Group performed a phase III trial in
which patients with advanced NSCLC who had previously failed
platinum-containing chemotherapy were randomised to 75 or
100mgm
 2 docetaxel or a reference regimen of vinorelbine or
ifosfamide (Fossella et al, 2000). Overall response rates were
6.7 and 10.8% with 75 and 100mgm
 2 docetaxel, respectively, each
significantly higher than the 0.8% response with vinorelbine or
ifosfamide. Overall survival did not differ significantly between the
three groups, although the 1-year survival was significantly greater
with 75mgm
 2 docetaxel than the control treatment.
In another trial, patients with NSCLC were randomised to either
docetaxel or best supportive care (Shepherd et al, 2000). Docetaxel
was initially administered at 100mgm
 2 every 21 days, but was
later reduced to 75mgm
 2 every 21 days due to an unacceptable
toxic death rate at the higher dose. Despite low overall response
rates, patients treated with docetaxel survived longer. The overall
response rate for docetaxel, based on 84 patients with measurable
lesions, was 7.1%. The median survival was 7.0 months for patients
receiving docetaxel compared with 4.6 months for patients
receiving best supportive care. Quality-of-life analysis demon-
strated less worsening of PS and less use of tumour-related
medications for docetaxel-treated patients.
Although docetaxel appears to demonstrate the most consistent
efficacy as a second-line treatment and has recently been approved
for first-line treatment when combined with cisplatin, it is
associated with a high incidence of haematological toxicity. An
alternative chemotherapy treatment option is the experimental
agent pemetrexed, a new antifolate. In a phase III study in
previously treated patients with recurrent NSCLC, pemetrexed
(used with vitamin supplements) had a more favourable haema-
tological toxicity profile when compared with docetaxel (Hanna
et al, 2003); patients experienced less severe neutropenia, fewer
hospitalisations and less need for granulocyte colony-stimulating
factor/granulocyte–macrophage colony-stimulating factor sup-
port. Pemetrexed therapy, while less toxic, was still associated
with haematological toxicity, hospital admissions and haematolo-
gical growth factor support, and did not improve overall outcome
compared with docetaxel; hence, there is still an unmet need for
efficacious, well-tolerated treatment options.
The therapeutic ratios of chemotherapy regimens
In making decisions for treatment regimens, it is necessary to
consider the overall therapeutic index, that is, not just the response
rate or survival but also the toxicity of treatment and the
subsequent outcomes. Cytotoxic chemotherapy regimens are often
associated with significant toxicity, which has a detrimental effect
on a patient’s QoL. Furthermore, such toxicity may result in a
patient opting not to receive chemotherapy. Indeed, in a recent
study assessing the treatment preferences of patients with lung
cancer, only 22% said they would choose chemotherapy over best
supportive care for a 3-month improvement in survival, while the
majority (68%) would choose chemotherapy if it substantially
reduced symptoms without an improvement in survival (Silvestri
et al, 1998).
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NSCLC
Chemotherapy treatment and supportive care to manage some
unwanted side effects has progressed in the past decade. Indeed,
the new doublet treatment regimens provide advantages for
patients and some improvement in survival and QoL over the
older chemotherapy regimens. Despite these advances in treat-
ment, improvements in the survival of patients with NSCLC in
recent years have been modest. For patients with advanced disease
with good enough PS to tolerate and thus receive third- or fourth-
line chemotherapy, a retrospective analysis reported the median
overall survival from the start of the last treatment as 4 months
(Figure 2) (Massarelli et al, 2003).
Clinical data over the past decade show that there is unlikely to
be further significant improvement in outcome using conventional
treatment and, as there are few options for patients who have
relapsed following chemotherapy, there is an unmet need for the
treatment of NSCLC.
The trend of not receiving any chemotherapy with curative
intent is especially common among elderly patients. In a study of
the management of 6300 Medicare patients aged 465 years who
were diagnosed with stage IV NSCLC, the authors found that only
21.5% received chemotherapy for metastatic disease (Earle et al,
2000). They noted that despite the fact that all patients had the
same health insurance cover, the use of chemotherapy was far from
consistent for all beneficiaries. In this cohort, younger patients and
those with few comorbid conditions were more likely to receive
chemotherapy but several nonmedical factors, such as nonblack
race, higher socioeconomic status, treatment in a teaching hospital
and living in certain urban areas, also significantly increased a
patient’s likelihood of receiving chemotherapy (Earle et al, 2000).
Scepticism towards treatment was also common among Canadian
physicians; only 20% thought that treating advanced NSCLC with
chemotherapy was worthwhile (Raby et al, 1995). In the UK, only
11% of clinicians recommended chemotherapy for appropriate
elderly patients, whereas 26% advised therapy if the patient was
o50 years of age (Crook et al, 1997). New modalities of therapy
may improve these numbers and increase the percentage of treated
patients.
GEFITINIB: A NOVEL TARGETED THERAPY FOR
NSCLC
Epidermal growth factor receptor (EGFR)
The EGFR is expressed in a wide range of solid tumours and is
associated with a poor prognosis in several malignancies. Indeed,
evidence for a role for the EGFR in the inhibition and pathogenesis
of various cancers has led to the development of agents that target
this receptor. Those most advanced in development are the EGFR
tyrosine kinase inhibitors (EGFR-TKIs) gefitinib (‘Iressa’) and
erlotinib (‘Tarceva’), and the monoclonal antibody cetuximab
(‘Erbitux’).
Clinical trials with gefitinib
Gefitinib is the EGFR-TKI with the most extensive clinical
experience, particularly in NSCLC. Based on data from two pivotal
phase II trials, IDEAL (‘Iressa’ Dose Evaluation in Advanced Lung
cancer) 1 and 2 (Fukuoka et al, 2003a; Kris et al, 2003), gefitinib
250mg once daily was recently approved for use in patients with
previously treated advanced NSCLC in Japan, the USA and other
countries. Patients in both studies had been pretreated and, while
all patients had a poor prognosis, patients in IDEAL 1 had a better
prognosis than those in IDEAL 2. In IDEAL 1, patients had
received one or two prior chemotherapy regimens (at least one
platinum based), whereas in IDEAL 2 all patients had received two
or more prior chemotherapy regimens (which must have included
platinum and docetaxel). All had received their last dose of
chemotherapy within the previous 90 days and had recurrent
disease or were unable to tolerate further chemotherapy, usually as
a result of chemotherapy-associated neuropathy. Furthermore, all
patients in IDEAL 2 and 66.7% of patients in IDEAL 1 were
symptomatic at trial entry. At the recommended dose of
250mgday
 1, the objective tumour response rates were 18.4 and
11.8% in IDEAL 1 and 2, respectively. Objective responses
observed in patients with large or bulky measurable tumours
and in patients with extensive, nonmeasurable disease were also
durable; median durations of response at 250mgday
 1 were 13.0
and 7.0 months in IDEAL 1 and 2, respectively (Fukuoka et al,
2003b). Survival data were encouraging and disease control rates
(response plus stable disease) showed that almost half of the
patients treated with gefitinib in both trials benefited from
treatment: median survival rates at 250mgday
 1 were 7.6 and
6.5 months in IDEAL 1 and 2, respectively; disease control rates at
250mgday
 1 were 54.4 and 42.2%, respectively. In both IDEAL 1
and 2, disease-related symptoms improved significantly for many
patients. At the recommended dose of 250mgday
 1 gefitinib, 40.3
and 43.1% of symptomatic patients in IDEAL 1 and 2, respectively,
experienced improvement in their disease-related symptoms that
lasted for at least 1 month. Symptom relief was also rapid: the
median time to onset of improvement was 8 days in IDEAL 1 and
10 days in IDEAL 2 (the times of the first postbaseline assessment
for each study).
Results of preliminary studies suggested that first-line combina-
tion therapy with gefitinib and platinum-based chemotherapy is
feasible and support further investigation of these combinations in
NSCLC. However, in the phase III combination trials INTACT
(‘Iressa’ NSCLC Trial Assessing Combination Treatment) 1 and 2,
which involved 42100 chemonaive patients with advanced
NSCLC, gefitinib provided no additional survival benefit in the
first-line setting. Nevertheless, results confirmed the safety role of
gefitinib in a placebo-controlled setting (Johnson et al, 2002): there
was no worsening of chemotherapy-associated toxicities and the
observed side effects of skin rash, acne and diarrhoea were as
predicted from the IDEAL trials. In light of monotherapy activity,
the reasons for the lack of increased activity in combination
therapy are yet to be determined, although current studies are
trying to analyse retrospectively the biological profile of respon-
ders vs nonresponders.
ADVANCES IN THE TREATMENT OF NSCLC IN JAPAN
The Japanese incidence rates of NSCLC
Lung cancer remains the leading cause of cancer-related death in
Japan despite efforts to promote early detection and surgery.
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Figure 2 Median overall survival time for each line of treatment
(Massarelli et al, 2003). Reprinted from: Massarelli et al (2003). Copyright
(2003), with permission from Elsevier.
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Welfare show approximately 55000 deaths from lung cancer yearly
in Japan and predict an 80% increase in incidence over the next
15 years.
Types of treatment for lung cancer
Globally, surgery is the treatment of choice for patients with stage I
and II NSCLC and for patients with advanced disease, the principal
forms of treatment are radiation therapy, chemotherapy, surgery
and a combination of these options. In Japan, in contrast to the
rest of the world, surgery is the primary treatment option offered
to those with advanced disease. UFT, a combination of tegafur and
uracil, is also widely available in Japan, where researchers have
demonstrated the utility of this agent as adjuvant therapy after
surgical resection, whether alone or in combination with cisplatin
and vindesine (Langer, 1999). Further research is required to
determine whether this agent will have a role in treatment of
NSCLC outside Japan.
Preferred chemotherapy regimens in Japan
In Japan, platinum-based regimens are the preferred standard
chemotherapy for NSCLC at present. However, chemotherapy for
NSCLC in Japan is controversial because the differences in the
efficacies of combination chemotherapies, including new agents
such as irinotecan, paclitaxel and vinorelbine, have not been
recognised in randomised controlled trials. The Four-Arm
Cooperative Study for advanced NSCLC is an ongoing postmarket-
ing clinical trial in Japan that was designed to compare three
platinum-based combination regimens (carboplatin plus paclitax-
el, cisplatin plus gemcitabine and cisplatin plus vinorelbine) with
cisplatin plus irinotecan as the reference arm (Ohe et al, 2003)
(Figure 3). To date, similar response rates have been observed in
all four treatment arms. Toxicity was also a feature of each
treatment arm: thrombocytopenia and diarrhoea were very
common. There is no ‘Gold Standard’ therapy for the treatment
of NSCLC in Japan and the development of new agents,
particularly molecular-target-based drugs such as gefitinib, is
necessary to further improve therapeutic results in lung cancer.
Approximately 37000 patients have received gefitinib in Japan
and, up to January 2003, 84 patients had received gefitinib in
clinical practice at the Tokyo Medical University (Table 2). Overall,
the partial response rate was 15.5% and stable disease rate was
45.2%. In this difficult-to-treat patient population, the median time
to disease progression was 4 months. Gefitinib was generally well
tolerated: grade 3/4 AEs included one pulmonary, one skin and
one hepatic event. Individual patients also experienced improve-
ment in QoL. For example, a patient with NSCLC liver metastases
was able to perform activities not previously possible following the
administration of gefitinib. Furthermore, an improvement in liver
function was observed.
The incidence of interstitial lung disease (ILD) in patients
treated with gefitinib in Japan was recently reported as being 2%
(Forsythe and Faulkner, 2003). However, the reported incidence of
ILD in 480000 patients who have received gefitinib worldwide is
approximately 1%, and it is 0.3% in a worldwide compassionate-
use programme in 438000 patients, in which investigators must
submit safety data (Forsythe and Faulkner, 2003). Although
vigilance for pulmonary toxicity is mandatory, in this area of
high unmet clinical need, the benefits of gefitinib outweigh the
risks in patients for whom no other proven effective treatment
option exists.
Primary end point
Cisplatin 80 mg m−2, day 1
Irinotecan 60 mg m−2, days 1, 8, 
15 q 4 weeks overall survival
Secondary end points
response rate
response duration
time to progression
time to treatment failure
QoL
Carboplatin AUC 6 mg ml−1 min−1, day 1
Paclitaxel 200 mg m−2, day 1
q 3 weeks
Cisplatin 80 mg m−2, day 1
Gemcitabine 1000 mg m−2,
days 1, 8 q 3 weeks
Cisplatin 80 mg m−2, day 1
Vinorelbine 25 mg m−2, days 1, 8 
q 3 weeks
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600 patients
Untreated
(IIIb) or IV
PS: 0−1
Age: <75 years
*
*Cisplatin plus irinotecan as the reference arm
Figure 3 Four-Arm Cooperative Study for advanced NSCLC in Japan: trial design.
Table 2 Tokyo Medical University experiences with gefitinib: patient
demography
Gefitinib, 250mgday
 1
No. patients treated 84
Mean (range) age, years 65.5 (35–87)
Male:female, n 44:40
Performance status, n
0–1 75
29
Tumour histology, n
Adenocarcinoma 68
Nonadenocarcinoma 16
Disease stage
IV 32
III a/b 10/23
II a/b 1/0
Postoperative 18
Previous cancer treatment, n
0 prior regimens 1
1 prior regimen 35
X2 prior regimens 48
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tolerability profile and oral bioavailability in patients with
advanced NSCLC who have previously received treatment with
cytotoxic chemotherapy, has led to the development of a
programme of clinical trials to define the further potential of
gefitinib in NSCLC. In Japan, planned or ongoing trials will assess
the effect of gefitinib as monotherapy and in combination with
radiotherapy and chemotherapy. A translational research project is
also ongoing. The outcome of these and other trials may lead to
opportunities to change the current treatment strategies for
NSCLC.
Future therapies for NSCLC
Despite recent advances in treatment of NSCLC with chemother-
apeutic regimens, the prognosis for this patient population
remains poor. Molecular targets have recently been identified as
a result of advances in molecular biology; subsequently, many
novel categories of anticancer drugs have been developed. One
example of this approach is a better understanding of growth
signalling pathways. The EGF pathway contributes to the
malignant potential of NSCLC and several compounds have been
developed to selectively block this pathway, for example, the
EGFR-TKIs gefitinib and erlotinib and the monoclonal antibody
cetuximab. Most advanced in research are the TKIs, which have
demonstrated similar efficacy and safety profiles. Gefitinib is the
agent with the most extensive clinical experience and recently it
was approved for use as a monotherapy in patients with previously
treated advanced NSCLC in Japan, the USA and other countries.
Thus, gefitinib is already providing responses and disease
stabilisation in patients with NSCLC and no other treatment
options.
Further research is required to better understand the role of the
EGFR in NSCLC since its significance in individual tumours has
not yet been fully identified. Determining the specific cases in
which the EGFR plays a pivotal function in carcinogenesis may
help to recognise those patients who may benefit from therapy
with EGFR inhibitors. Several research directions address this
issue: animal studies have demonstrated that EGFR-TKIs have a
better antitumour effect when both the tumour and the tumour-
associated endothelial cells express the target receptor (Baker et al,
2002); and human NSCLC tumour analyses have shown that
coexpression of both the EGFR and HER2 affected survival more
than either of the receptors alone (Brabender et al, 2001; Onn et al,
2004). In addition to studies of the role of the EGFR in NSCLC,
investigation of different combination therapies is still required
and the sequencing of biological compounds with conventional
chemotherapy or radiotherapy may provide evidence for directing
future studies. Indeed, the molecular diversity of tumours may
ultimately necessitate a combination of biological agents to
maximise therapeutic effects.
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